Evolus Inc
EOLS · NASDAQ
Evolus is a performance beauty company with a customer-centric approach focused on delivering breakthrough products. In 2019, the U.S. Food and Drug Administration approved Jeuveau® (prabotulinumtoxinA-xvfs), the first and only neurotoxin dedicated exclusively to aesthetics and manufactured in a state-of-the-art facility using Hi-Pure™ technology. Jeuveau® is powered by Evolus' unique technology platform and is designed to transform the aesthetic market by eliminating the friction points existing for customers today.
ESG Scores
Overall ESG3.9
Environmental4.1
Social2.3
Governance5.7
Gender Diversity
Female Directors0.375%
Female Executives0.2127659574468085%
Women in Workforce0.6890000000000001%
CEO GenderMale